| SRJ Technologies Group plc (SRJ) CHESS DEPOSITARY INTERESTS 1:1 |
Energy |
$21 |
BoltEx order secured from leader in offshore energy solution
|
31 Oct 2025 9:11AM |
$0.014 |
$0.015 |
risen by
7.14%
|
|
SRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- SRJ secures BoltEx® supply contract with Storm Procurement Limited.
- Contract valued at US$269k (A$410k) for FPSO operator in Guyana.
- First adoption of full BoltEx® range by the FPSO operator.
- Enhances asset integrity and safety, addresses flange corrosion issues.
- Includes advanced payment terms, differing from standard conditions.
- Aims to expand product utilization and improve operational efficiency.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Anteris Technologies Ltd (AVR) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$316 |
Schedule 14A Preliminary Proxy Statement
|
31 Oct 2025 9:11AM |
$7.500 |
$7.660 |
risen by
2.13%
|
|
| EV Resources Limited (EVR) ORDINARY FULLY PAID |
Materials |
$27 |
Director On Market Purchase
|
31 Oct 2025 9:09AM |
$0.010 |
$0.009 |
fallen by
10%
|
|
| Energy One Limited (EOL) ORDINARY FULLY PAID |
Information Technology |
$546 |
Application for quotation of securities - EOL
|
31 Oct 2025 9:08AM |
$18.410 |
$17.350 |
fallen by
5.76%
|
|
| White Cliff Minerals Limited (WCN) ORDINARY FULLY PAID |
Materials |
$46 |
Completion of Sale of Reedy South Gold Project
|
31 Oct 2025 9:08AM |
$0.020 |
$0.018 |
fallen by
10%
|
|
WCN - Price-sensitive ASX Announcement
Full Release
Key Points
- Final payment of A$1 million received for Reedy South Gold Project.
- Sale concluded from previous agreement of A$1.2 million in cash.
- White Cliff Minerals to focus on Canadian projects, specifically Rae Copper Silver Project.
- Completion marks divestment of remaining Australian assets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BCAL Diagnostics Limited (BDX) ORDINARY FULLY PAID |
Health Care |
$39 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Oct 2025 9:08AM |
$0.090 |
$0.105 |
risen by
16.67%
|
|
BDX - Price-sensitive ASX Announcement
Full Release
Key Points
- Net cash balance of $1.6 million at September 2025 end.
- Invested $1.6 million in R&D for the quarter.
- Convertible note facility of $10 million with $5 million committed.
- Anticipated $1.2 million R&D tax refund in the next quarter.
- Continued focus on BREASTESTplus™ commercial rollout.
- Operations expected to continue with convertible note funding and R&D refund.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Integral Diagnostics Limited (IDX) ORDINARY FULLY PAID |
Health Care |
$947 |
AGM - CEO's Address and Presentation
|
31 Oct 2025 9:08AM |
$2.480 |
$2.540 |
risen by
2.42%
|
|
IDX - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue grew by 33.7% to $628 million in FY25.
- Operating EBITDA increased by 38.3% to $126.5 million.
- Successful merger integration with Capitol Health.
- Expansion of teleradiology and opening of new clinics.
- Focus on radiologist recruitment and operational efficiencies.
- Proactive capital allocation to enhance patient care.
- Strong industry position with growth in high-value modalities.
- Strategic priorities include further integration and digital advancements.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Green360 Technologies Limited (GT3) ORDINARY FULLY PAID |
Materials |
$47 |
Green360 Achieves Major Milestone with EcoClay
|
31 Oct 2025 9:08AM |
$0.034 |
$0.039 |
risen by
14.71%
|
|
GT3 - Price-sensitive ASX Announcement
Full Release
Key Points
- Eco-Clay is a high-reactivity calcined kaolinite material.
- Eco-Clay can replace up to 40% of Portland cement in concrete.
- Independent verification by the University of Melbourne.
- Eco-Clay offers a cost advantage as it is produced from by-products.
- The product meets Australian and international standards for SCM.
- Eco-Clay has been tested and found suitable for Grade 1 pozzolan.
- Green360's approach aligns with circular economy principles.
- Market opportunity exists due to the global push for low-carbon materials.
- Engagement with industry and government stakeholders is underway.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Foundation Investment Company Limited (AFI) ORDINARY FULLY PAID |
Financials |
$9,009 |
Update - Notification of buy-back - AFI
|
31 Oct 2025 9:08AM |
$7.400 |
$7.190 |
fallen by
2.84%
|
|
| Core Lithium Ltd (CXO) ORDINARY FULLY PAID |
Materials |
$732 |
Small Share Sale Facility
|
31 Oct 2025 9:08AM |
$0.120 |
$0.275 |
risen by
129.17%
|
|
| AMCIL Limited (AMH) ORDINARY FULLY PAID |
Financials |
$319 |
Update - Notification of buy-back - AMH
|
31 Oct 2025 9:08AM |
$1.080 |
$1.010 |
fallen by
6.48%
|
|
| Acusensus Limited (ACE) ORDINARY FULLY PAID |
Information Technology |
$276 |
Speed Camera Contract Expansion in Queensland
|
31 Oct 2025 9:07AM |
$1.800 |
$1.700 |
fallen by
5.56%
|
|
ACE - Price-sensitive ASX Announcement
Full Release
Key Points
- Queensland Department of Transport and Main Roads expanded contract with Acusensus.
- Doubling of trailer-based speed enforcement units.
- Deployment from November 2025 through 2026.
- Contract value approximately $16.6 million.
- 92% decline in excessive speeding with current program.
- Each unit to operate for an initial five-year term.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BSA Limited (BSA) ORDINARY FULLY PAID |
Industrials |
$11 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Oct 2025 9:07AM |
$0.130 |
$0.150 |
risen by
15.38%
|
|
BSA - Price-sensitive ASX Announcement
Full Release
Key Points
- Operating cash flow decline to ($4.7 million) due to redundancy-related cash outflows and volume drops.
- Net cash position at quarter's end was $19.0 million with no external borrowings.
- Revenue fell significantly to $17.5 million, a 77% decrease from the previous year.
- EBITDA for the period was $3.9 million, supported by transition payments.
- Staff restructuring in progress due to contract losses, with staff reduced from 150 to 50.
- Focus on refining operations and targeting growth opportunities in electric vehicle charging.
- The company is strategically managing unprofitable trading and assessing future directions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bubs Australia Limited (BUB) ORDINARY FULLY PAID |
Consumer Staple |
$123 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Oct 2025 9:07AM |
$0.165 |
$0.138 |
fallen by
16.67%
|
|
BUB - Price-sensitive ASX Announcement
Full Release
Key Points
- Net revenue increased by 30% to $25.6 million.
- Gross profit margin rose to 46.4%.
- EBITDA achieved at $0.5 million.
- Cash reserves at $12.9 million, with $10 million in undrawn facilities.
- Negative operating cash flow due to inventory rebuild.
- Key personnel change: Jasmin Manner as President USA.
- Inventory challenges expected to be resolved by end of the current quarter.
- Anticipated FDA approval by end of 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| PainChek Ltd (PCK) ORDINARY FULLY PAID |
Health Care |
$61 |
Investor Presentation
|
31 Oct 2025 9:07AM |
$0.046 |
$0.290 |
risen by
530.43%
|
|
PCK - Price-sensitive ASX Announcement
Full Release
Key Points
- 115,000 contracted licenses with $5.6 million ARR.
- FDA De Novo clearance for PainChek app in the US.
- Expansion into infant care with the PainChek Infant app.
- Regulatory clearance in ANZ, EU, and pending in the US.
- Projected ARR target covers core operating costs in ANZ and UK.
- Strong pipeline of 47,000 new licenses.
- Focus on B2C and B2B markets for global market penetration.
- PainChek Ltd is targeting an operational break-even point in ANZ and UK.
- Consistent growth in clinical utility and world's largest pain database.
- Strategic partnerships and integrations with major healthcare systems.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Integral Diagnostics Limited (IDX) ORDINARY FULLY PAID |
Health Care |
$947 |
AGM - Chair's Address and Presentation
|
31 Oct 2025 9:07AM |
$2.480 |
$2.540 |
risen by
2.42%
|
|
| Globe Metals & Mining Limited (GBE) ORDINARY FULLY PAID |
Materials |
$43 |
Appendix 4G and Corporate Governance Statement
|
31 Oct 2025 9:06AM |
$0.049 |
$0.046 |
fallen by
6.12%
|
|
| Racura Oncology Ltd (RAC) ORDINARY FULLY PAID |
Health Care |
$494 |
September 2025 Quarterly Activity Report and Appendix 4C
|
31 Oct 2025 9:06AM |
$3.500 |
$2.730 |
fallen by
22%
|
|
RAC - Price-sensitive ASX Announcement
Full Release
Key Points
- Discovery and filing of three patents for (E,E)-isoform of bisantrene.
- Phase 1 cardioprotection and anticancer trial of RC220 is ongoing.
- Regulatory approvals received in Hong Kong and South Korea.
- Cash and equivalents of $11.27 million as of September 2025.
- Significant focus on R&D and drug manufacturing.
- Additional $3.6 million funding raised through option conversions.
- (E,E)-bisantrene's mechanism involves G-quadruplex binding affecting cancer genes.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| PainChek Ltd (PCK) ORDINARY FULLY PAID |
Health Care |
$61 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Oct 2025 9:06AM |
$0.046 |
$0.290 |
risen by
530.43%
|
|
PCK - Price-sensitive ASX Announcement
Full Release
Key Points
- FDA De Novo clearance for PainChek Adult App in the US.
- Entry into the $175 million annual US long-term care market.
- 115,770 contracted licenses globally with an ARR of $5.6 million.
- Cash reserves of $6.3 million as of 30 September 2025.
- First US commercial agreement signed post-FDA clearance.
- PainChek Infant App targets $15 billion global market opportunity.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pathkey.AI Ltd (PKY) ORDINARY FULLY PAID |
Information Technology |
$5 |
Quarterly Activities & Cashflow Report
|
31 Oct 2025 9:06AM |
$0.020 |
$0.016 |
fallen by
20%
|
|
PKY - Price-sensitive ASX Announcement
Full Release
Key Points
- Pathkey.AI's core platform, TrialKey, improves clinical trial success rates using AI.
- Cash position at the end of the quarter was $334,000.
- Net cash used in operating activities was $236,000.
- No cash receipts from customers during the quarter.
- Company plans to raise additional capital through equity securities.
- Pathkey is focusing on expanding market engagement and AI capabilities.
- Investments in AI-driven drug discovery and compound repurposing are ongoing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Globe Metals & Mining Limited (GBE) ORDINARY FULLY PAID |
Materials |
$43 |
Annual Report to Shareholders
|
31 Oct 2025 9:05AM |
$0.049 |
$0.046 |
fallen by
6.12%
|
|
| Nuchev Limited (NUC) ORDINARY FULLY PAID |
Consumer Staple |
$19 |
Corporate Governance Statement and Appendix 4G
|
31 Oct 2025 9:05AM |
$0.140 |
$0.125 |
fallen by
10.71%
|
|
| Mach7 Technologies Limited (M7T) ORDINARY FULLY PAID |
Health Care |
$145 |
Q1 FY26 Results Presentation
|
31 Oct 2025 9:05AM |
$0.295 |
$0.615 |
risen by
108.47%
|
|
M7T - Price-sensitive ASX Announcement
Full Release
Key Points
- Mach7 Technologies reports Q1 FY26 financial highlights.
- CARR reached A$29.6 million, with a TCV of A$2.6 million.
- Closing cash reported at A$18.9 million with no debt.
- Focus on commercial transformation and operational efficiencies.
- Building intelligent imaging ecosystems and leveraging AI.
- Product innovation includes a new tele-imaging platform.
- Targeting growth in radiology, cardiology, and oncology markets.
- Emphasizing profitable growth through innovation and accountability.
- Share buy-back program paused pending strategic review.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nuchev Limited (NUC) ORDINARY FULLY PAID |
Consumer Staple |
$19 |
Annual Report to Shareholders
|
31 Oct 2025 9:05AM |
$0.140 |
$0.125 |
fallen by
10.71%
|
|
| Cuscal Limited (CCL) ORDINARY FULLY PAID |
Financials |
$847 |
Results of 2025 AGM
|
31 Oct 2025 9:04AM |
$4.150 |
$4.420 |
risen by
6.51%
|
|
Call 1300 880 160
Start a chat
Schedule a call
